Market Research Logo

Regeneron Pharmaceuticals Inc (REGN) - Financial and Strategic SWOT Analysis Review

Regeneron Pharmaceuticals Inc (REGN) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Regeneron Pharmaceuticals Inc (Regeneron) is a biopharmaceutical company, which discovers, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The company’s six US FDA-approved medicines and product candidates in development help patients with eye diseases, asthma, pain, cancer and heart, allergic, inflammatory and infectious diseases. It develops products based on its VelociSuite technology platforms, which include VelociGene, VelocImmune, VelociMouse, VelociMab and other related technologies. Regeneron also has various product candidates under clinical development for treating asthma, pain, cancer, atopic dermatitis and infectious diseases. It has subsidiaries in Belgium, Spain, Ireland, the Netherlands, the US and the UK. Regeneron is headquartered in Tarrytown, New York, the US.

Regeneron Pharmaceuticals Inc Key Recent Developments

Feb 25,2019 Sanofi Positive results presented from two Phase 3 trials of Dupixent dupilumab in severe chronic rhinosinusitis with nasal polyps
Feb 11,2019 Regeneron and Sanofi Offer Praluent (alirocumab) at a New Reduced U.S. List Price
Feb 06,2019 Regeneron reports fourth quarter and full year 2018 financial and operating results
Jan 21,2019 ISA Pharmaceuticals Announces Start of Phase 2 Combination Trial of ISA101b and Regeneron s Cemiplimab in Oropharyngeal Cancer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Regeneron Pharmaceuticals Inc - Key Facts
Regeneron Pharmaceuticals Inc - Key Employees
Regeneron Pharmaceuticals Inc - Key Employee Biographies
Regeneron Pharmaceuticals Inc - Major Products and Services
Regeneron Pharmaceuticals Inc - History
Regeneron Pharmaceuticals Inc - Company Statement
Regeneron Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 - Company Analysis
Company Overview
Regeneron Pharmaceuticals Inc - Business Description
Product Category: Arcalyst
Overview
Performance
Product Category: Dupixent
Overview
Product Category: Eylea
Overview
Performance
Product Category: Kevzara
Overview
Product Category: Praluent
Overview
Product Category: Zaltrap
Overview
Product Category: Product Category
Performance
R&D Overview
Regeneron Pharmaceuticals Inc - Corporate Strategy
Regeneron Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Regeneron Pharmaceuticals Inc - Strengths
Regeneron Pharmaceuticals Inc - Weaknesses
Regeneron Pharmaceuticals Inc - Opportunities
Regeneron Pharmaceuticals Inc - Threats
Regeneron Pharmaceuticals Inc - Key Competitors
Section 3 - Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Regeneron Pharmaceuticals Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
Feb 25, 2019: Sanofi Positive results presented from two Phase 3 trials of Dupixent dupilumab in severe chronic rhinosinusitis with nasal polyps
Feb 11, 2019: Regeneron and Sanofi Offer Praluent (alirocumab) at a New Reduced U.S. List Price
Feb 06, 2019: Regeneron reports fourth quarter and full year 2018 financial and operating results
Jan 21, 2019: ISA Pharmaceuticals Announces Start of Phase 2 Combination Trial of ISA101b and Regeneron s Cemiplimab in Oropharyngeal Cancer
Jan 09, 2019: Adimab provides 2018 update on clinical pipeline
Jan 07, 2019: Sanofi ends immuno-oncology discovery with...
Jan 07, 2019: Regeneron Provides Update on Commercial and Pipeline Progress at J.P. Morgan Healthcare Conference
Dec 20, 2018: Merus Announces Global Settlement and End to All Patent Litigation with Regeneron Pharmaceuticals
Nov 27, 2018: Clinical trial of investigational Ebola treatments begins in the Democratic Republic of the Congo
Nov 13, 2018: Health officials to launch new Ebola drug trial
Section 6 - Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Regeneron Pharmaceuticals Inc, Key Facts
Regeneron Pharmaceuticals Inc, Key Employees
Regeneron Pharmaceuticals Inc, Key Employee Biographies
Regeneron Pharmaceuticals Inc, Major Products and Services
Regeneron Pharmaceuticals Inc, History
Regeneron Pharmaceuticals Inc, Other Locations
Regeneron Pharmaceuticals Inc, Subsidiaries
Regeneron Pharmaceuticals Inc, Key Competitors
Regeneron Pharmaceuticals Inc, Ratios based on current share price
Regeneron Pharmaceuticals Inc, Annual Ratios
Regeneron Pharmaceuticals Inc, Annual Ratios (Cont...1)
Regeneron Pharmaceuticals Inc, Annual Ratios (Cont...2)
Regeneron Pharmaceuticals Inc, Interim Ratios
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Regeneron Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Regeneron Pharmaceuticals Inc, Performance Chart (2014 - 2018)
Regeneron Pharmaceuticals Inc, Ratio Charts
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report